research use only
Cat.No.S3102
|
In vitro |
Water : 23 mg/mL
DMSO
: Insoluble
Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 113.12 | Formula | C4H7N3O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 60-27-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | NSC13123 | Smiles | CN1CC(=O)N=C1N | ||
| In vitro |
Creatinine is a break-down product of creatine phosphate in muscle, and is usually produced at a fairly constant rate by the body. This compound's levels in blood and urine may be used to calculate the creatinine clearance (CrCl), which reflects the glomerular filtration rate (GFR), an important clinical index of renal function. |
References |
|
|---|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04598516 | Withdrawn | Acute Kidney Injury (Nontraumatic)|Contrast-induced Nephropathy|Renal Insufficiency |
Maastricht University Medical Center |
November 1 2097 | -- |
| NCT04597892 | Withdrawn | Renal Insufficiency|Acute Kidney Injury|Contrast-induced Nephropathy |
Maastricht University Medical Center |
May 1 2097 | -- |
| NCT06226662 | Not yet recruiting | Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis |
NovelMed Therapeutics |
June 2025 | Phase 2 |
| NCT05847179 | Not yet recruiting | Werner Syndrome |
PRG Science & Technology Co. Ltd. |
January 1 2025 | Phase 2 |
| NCT05935293 | Not yet recruiting | Renal Transplantation|Dexmedetomidine |
Eduardo Schiffer|University Hospital Geneva |
December 1 2024 | Phase 4 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.